Latest Insider Transactions at Genelux Corp (GNLX)
This section provides a real-time view of insider transactions for Genelux Corp (GNLX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of GENELUX CORP to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of GENELUX CORP's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 11
2023
|
Ralph Smalling Head of Regulatory |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+45.32%
|
-
|
|
Sep 08
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
24,831
-5.54%
|
$571,113
$23.49 P/Share
|
|
Sep 07
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
12,446
-3.72%
|
$298,704
$24.73 P/Share
|
|
Aug 30
2023
|
Tony Yu VP, Clinical Trial Operations |
SELL
Open market or private sale
|
Direct |
19,800
-12.71%
|
$475,200
$24.7 P/Share
|
|
Aug 18
2023
|
Tony Yu VP, Clinical Trial Operations |
SELL
Open market or private sale
|
Direct |
3,265
-2.05%
|
$75,095
$23.73 P/Share
|
|
Aug 18
2023
|
Joseph Cappello VP, Pharmaceutical Development |
SELL
Open market or private sale
|
Direct |
3,265
-36.28%
|
$75,095
$23.73 P/Share
|
|
Aug 18
2023
|
Sean Ryder General Counsel |
SELL
Open market or private sale
|
Direct |
328
-36.44%
|
$7,544
$23.73 P/Share
|
|
Aug 18
2023
|
Doug Samuelson Vice President, Finance |
SELL
Open market or private sale
|
Direct |
1,297
-36.03%
|
$29,831
$23.73 P/Share
|
|
Aug 18
2023
|
Ralph Smalling Head of Regulatory |
SELL
Open market or private sale
|
Direct |
935
-31.17%
|
$21,505
$23.73 P/Share
|
|
Aug 18
2023
|
Caroline Jewett Head of Quality |
SELL
Open market or private sale
|
Direct |
515
-31.21%
|
$11,845
$23.73 P/Share
|
|
Aug 18
2023
|
Thomas Zindrick President and CEO |
SELL
Open market or private sale
|
Direct |
8,349
-36.3%
|
$192,027
$23.73 P/Share
|
|
Feb 27
2023
|
Thomas Zindrick President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
23,000
+50.0%
|
-
|
|
Feb 17
2023
|
Gabe Woodward Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+19.28%
|
-
|
|
Feb 17
2023
|
Mary Mirabelli |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+50.0%
|
-
|
|
Feb 17
2023
|
James L Tyree |
BUY
Grant, award, or other acquisition
|
Direct |
9,000
+50.0%
|
-
|
|
Feb 17
2023
|
Sean Ryder General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
900
+50.0%
|
-
|
|
Feb 17
2023
|
Qian Zhang Associate VP, Research |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+4.13%
|
-
|
|
Feb 17
2023
|
John Thomas |
BUY
Grant, award, or other acquisition
|
Direct |
9,000
+1.84%
|
-
|
|
Feb 17
2023
|
Joseph Cappello VP, Pharmaceutical Development |
BUY
Grant, award, or other acquisition
|
Direct |
9,000
+50.0%
|
-
|
|
Feb 17
2023
|
Tony Yu VP, Clinical Trial Operations |
BUY
Grant, award, or other acquisition
|
Direct |
9,000
+5.36%
|
-
|
|
Feb 17
2023
|
Doug Samuelson Vice President, Finance |
BUY
Grant, award, or other acquisition
|
Direct |
3,600
+50.0%
|
-
|
|
Jan 30
2023
|
Aladar Szalay |
BUY
Conversion of derivative security
|
Indirect |
1,000,000
+32.87%
|
-
|
|
Jan 30
2023
|
Gabe Woodward Director |
BUY
Conversion of derivative security
|
Indirect |
8,176
+50.0%
|
-
|
|
Jan 30
2023
|
Gabe Woodward Director |
BUY
Conversion of derivative security
|
Direct |
3,186
+50.0%
|
-
|
|
Jan 30
2023
|
John Thomas |
BUY
Conversion of derivative security
|
Direct |
470,000
+50.0%
|
-
|
|
Jan 26
2023
|
Qian Zhang Associate VP, Research |
BUY
Open market or private purchase
|
Indirect |
200
+50.0%
|
$1,200
$6.25 P/Share
|